- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12. | Sunshine Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| SUNSHINE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 09.12. | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus | 205 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
| 04.12. | Sunshine Biopharma, Inc.: Sunshine Biopharma Launches a New Generic Prescription Drug | 189 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / December 4, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
| 02.12. | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma | 156 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
| 22.11. | Sunshine Biopharma bringt generisches Lebermedikament in Kanada auf den Markt | 7 | Investing.com Deutsch | ||
| 22.11. | Sunshine Biopharma launches generic liver drug in Canada | 2 | Investing.com | ||
| 22.11. | Sunshine Biopharma, Inc.: Sunshine Biopharma Launches a New Generic Prescription Drug | 257 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
| 15.11. | Sunshine Biopharma stock hits 52-week low at $2.3 amid sharp decline | 4 | Investing.com | ||
| 15.11. | Sunshine Biopharma-Aktie erreicht 52-Wochen-Tief bei 2,3 US-Dollar | 3 | Investing.com Deutsch | ||
| 07.11. | Sunshine Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11. | Sunshine Biopharma reports Q3 results | 1 | Seeking Alpha | ||
| 06.11. | Sunshine Biopharma, Inc.: Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% | 359 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
| 05.11. | Sunshine Biopharma Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 23.10. | Sunshine Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.10. | Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 66.8% in September | 1 | MarketBeat | ||
| 26.09. | Sunshine Biopharma, Inc.: Sunshine Biopharma Launches Two New Generic Prescription Drugs | 170 | ACCESSWIRE | FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
| 10.09. | Sunshine Biopharma meets Nasdaq compliance requirements | 4 | Investing.com | ||
| 10.09. | Sunshine Biopharma, Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09. | Sunshine Biopharma reports potential SARS-CoV-2 treatment | 3 | Investing.com | ||
| 04.09. | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry | 197 | ACCESSWIRE | Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18%Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both... ► Artikel lesen |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,200 | +1,66 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| CASSAVA SCIENCES | 2,381 | +2,19 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 2,242 | -2,99 % | ORAMED PHARMACEUTICALS INC. - 8-K, Current Report | ||
| ROCKET LAB USA | 22,300 | +0,45 % | If You'd Invested $1,000 in Rocket Lab Stock 3 Years Ago, Here's How Much You'd Have Today | ||
| LIPOCINE | 5,090 | 0,00 % | Lipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis | SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| BOIRON | 26,350 | 0,00 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 34,100 | 0,00 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,069 | 0,00 % | Allergy Therapeutics shareholders approve AGM resolutions | ||
| MEDICINOVA | 2,020 | 0,00 % | MediciNova, Inc.: MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND | LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 1,610 | -1,83 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 | Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,460 | 0,00 % | Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside | ||
| CUMBERLAND PHARMACEUTICALS | 2,350 | 0,00 % | Cumberland Pharmaceuticals Inc.: FDA Approves Acetadote sNDA | - New Dosing Regimen Simplifies Administration -
NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty... ► Artikel lesen | |
| SHINECO | 2,210 | 0,00 % | Shineco Inc-Aktie erreicht 52-Wochen-Tief bei 2,05 US-Dollar | ||
| LYRA THERAPEUTICS | 0,174 | 0,00 % | Lyra Therapeutics, Inc. - 8-K, Current Report | ||
| REVIVA PHARMACEUTICALS | 1,440 | 0,00 % | Reviva announces pricing of $18M public offering of common stock and warrants |
Das Unternehmen SUNSHINE BIOPHARMA INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,82 % bei einem Aktienkurs von 2,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SUNSHINE BIOPHARMA INC finden Sie auf Wallstreet Online.
